Positron emission tomography in cardiovascular disease

Canadian Journal of Cardiology

Volumn 12, Issue 10, 1996, Pages 875-883

  Beanlands, Rob ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Metabolism; Myocardial bloodflow; Positron emission tomography (PET); Viability

Indexed keywords

ACETIC ACID C 11; AMMONIA; CARBON 11; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; HEART RECEPTOR; NITROGEN 13; OXYGEN 15; PALMITIC ACID C 11; RADIOISOTOPE; RUBIDIUM 82; TRACER;

AUTONOMIC NERVOUS SYSTEM; CANADA; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; HEALTH CARE AVAILABILITY; HEART MUSCLE BLOOD FLOW; HEART MUSCLE METABOLISM; HEART MUSCLE PERFUSION; HEART MUSCLE REVASCULARIZATION; HEART TRANSPLANTATION; HEART VENTRICLE FUNCTION; HUMAN; ISOTOPE LABELING; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; REVIEW;

CORONARY CIRCULATION; CORONARY DISEASE; DEOXYGLUCOSE; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HEART DISEASES; HEART TRANSPLANTATION; HUMANS; MYOCARDIUM; TISSUE SURVIVAL; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0029798759     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Schelbert H, Bonow R, Geltman E, Maddahi J, Schwaiger M. Position statement. Clinical use of cardiac positron emission tomography. Position paper of the Cardiovascular Council of the Society of Nuclear Medicine. J Nucl Med 1993;34:1385-8.
2. Costanzo MR, Augustine S, Bourge R, et al. Selection and treatment of candidates for heart transplantation. Circulation 1995;92:3593-612.
3. Schwaiger M, ed. Cardiac Positron Emission Tomography. Boston/Dordrecht/London: Kluwer Academic, 1996.
4. Beanlands R, deKemp R, Culbert P, et al. Myocardial glucose metabolism in severe ischemic left ventricular dysfunction. Can J Cardiol 1995;11(Suppl E):104E. (Abst)
5. Gould LK. PET perfusion imaging and nuclear cardiology. J Nucl Med 1991;32:579-606.
6. Go RT, Marwick TH, MacIntyre WJ, et al. A prospective comparison of rubidium-82 PET and thallium-201 SPECT myocardial perfusion imaging utilizing a single dipyridamole stress in the diagnosis of coronary artery disease J Nucl Med 1990;31:1899-905.
7. Stewart R, Schwaiger M, Molina M, et al. Comparison of rubidium-82 positron emission tomography and thallium-201 SPECT imaging for detection of coronary artery disease. Am J Cardiol 1991;67:1303-10.
8. Tamaki N, Yonekura Y, Senda M, et al Value and limitation of stress thallium-201 single photon emission computed tomography. comparison with nitrogen-13 ammonia positron tomography. J Nucl Med 1988;29:1181-8.
9. Beanlands R, Muzik O, Hutchins G, Schwaiger M. Noninvasive quantification of myocardial perfusion using positron emission tomography. Coronary Artery Dis 1992;3:281-90.
10. Patterson RE, Eisner RL, Horowitz SF. Comparison of cost-effectiveness and utility of exercise ECG, single photon emission computed tomography, positron emission tomography and coronary angiography for diagnosis of cornary artery disease. Circulation 1995,91:54-65.
11. Gould KL, Martucci JP, Goldberg DI, et al. Short term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease; A potential noninvasive marker of healing coronary endothelium. Circulation 1994;89:1530-8.
12. Bergmann S, Herrero P, Markham J, Winheimer C, Walsh M. Noninvasive quantification of myocardial blood flow in human subjects with oxygen-15-labeled water and positron emission tomography. J Am Coll Cardiol 1989;14:639-52.
13. Krivokapich J, Stevenson LW, Kobashigawa J, Huang S, Schelbert HR Quantification of absolute myocardial perfusion at rest and during exercise with positron emission tomography after human cardiac transplantation. J Am Coll Cardiol 1991;18:512-7.
14. Hutchins G, Schwaiger M, Rosenspire KC, Krivokapich J, Schelbert H, Kuhl D. Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging. J Am Coll Cardiol 1990,15:1032-42.
15. Herraro P, Markman J, Shelton ME, Weinheimer CJ, Bergmann SR. Noninvasive quantification of regional myocardial perfusion with rubidium-82 and positron emission tomography. Exploration of a mathematical model. Circulation 1990;82:1377-86.
16. Coxson PG, Brennan KM, Huesman RH, Lim S, Budinger TF. Variability and reproducibility of rubidium-82 kinetic parameters in the myocardium of the anesthetized canine. J Nucl Med 1995;36:287-96.
17. Geltman EM, Hennes GC, Senneff MJ, Sobel BE, Bergmann SR. Increased myocardial perfusion at rest and diminished perfusion reserve in patients with angina and angiographically normal coronary arteries. J Am Coll Cardiol 1990;16:586-95.
18. Krivokapich J, Stevenson LW, Kobashigawa J, Huang SS, Schelbert HR. Quantification of absolute myocardial perfusion at rest and during exercise with positron emission tomography after human cardiac transplantation. J Am Coll Cardiol 1991;18:512-7.
19. Camici P, Chiriatti G, Lorenzoni R, et al. Coronary vasodilation is impaired in both hypertrophied and non-hypertrophied myocardium of patients with hypertrophic cardiomyopathy. A study with nitrogen-13 ammonia and positron emission tomography. J Am Coll Cardiol 1991;17:879-86.
20. Walsh M, Geltman E, Steele R, et al. Augmented myocardial perfusion reserve ater coronary angioplasty quantified by positron emission tomography with O-15-H20. J Am Coll Cardiol 1990;15:119-27.
21. Beanlands R, Muzik O, Melon P, et al. Noninvasive quantification of regional myocardial flow reserve in stenosed and angiographically normal vessels of patients with coronary atherosclerosis. J Am Coll Cardiol 1995;26:1465-75
22. Uren NG, Melin JA, De Bruyne B, Wijins W, Baudhuin T, Camici PG. Relation between myocardial blood flow and the severity of coronary artery stenosis. N Engl J Med 1994;330:1782-8.
23. Uren NG, Marraccini P, Gistri R, deSilva R, Camici P. Altered coronary reserve and metabolsim in myocardium subtended by normal arteries in patients with coronary artery disease. J Am Coll Cardiol 1993;22:650-8.
24. Fallen EL, Nahmias C, Scheffel A, Coates G, Beanlands RSB, Garnet ES. Redistribution of myocardial blood flow with topical nitroglycerin in patients with coronary artery disease. A PET study. Circulation 1995;91:1381-8.
25. Ruddy TD, deKemp RA, Dalipaj MM, Aung MT, Vincent JS, Beanlands RS. Quantification of myocardial perfusion with Rb-82 and PET in myocardial infarction. Can J Cardiol 1996;12(Suppl E):155E. (Abst)
26. Beanlands R, Bach D, Raylman R, et al. Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using C-11 acetate kinetics in patients with dilated cardiomyopathy. J Am Coll Cardiol 1993;22:1389-98.
27. Gropler R, Shelton ME, Herrero P, Walsh JF, Bergmann SR. Measurement of myocardial oxygen consumption using positron emission tomography and C-11 acetate. Direct validation in human subjects. Circulation 1993;88:I-172. (Abst)
28. Gropler RJ, Geltman EM, Sampathkumaran K, et al. Comparison of carbon-11-acetate with fluorine-18-fluorodeoxyglucose for delineating viable myocardium by positron emission tomography. J Am Coll Cardiol 1993;22:1597
29. 11C acetate PET. Can J Cardiol 1995;11:293-300.
30. Camici P, Ferrannini E, Opie LH. Myocardial metabolism in ischemic heart disease. Basic principles and application to imaging by positron emission tomography. Prog Cardiovasc Dis 1989;XXXII:217-38.
31. Phelps ME, Hoffman EJ, Selin CE, et al. Investigation of [18-F]2-fluoro-2-deoxyglucose for the measure of myocadial glucose metbolism. J Nucl Med 1978;19:1311-9.
32. Marshall RC, Tillisch JH, Phelps ME, et al. Identification and differentiation of resting myocardial ischemia and infarction in man with positron computed tomography, 18F-labeled fluorodeoxyglucose and N-13 ammonia. Circulation 1983;67:766-78.
33. Rahimtoola SH. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation 1985;72:V123-V35.
34. Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986;314:884-8.
35. Carrel T, Jenni R, Haubold-Reuter S, von Schulthess G, Pasic M, Turina M. Improvement of severely reduced left ventricular function after surgical revascularization in patients with preoperative myocardial infarction. Eur J Cardiothorac Surg 1992;6:479-84.
36. Maddahi J, Heinrich S, Brunken R, Di Carli M. Role of thallium-201 and PET imaging in evaluation of myocardial viability and management of patients with coronary artery disease and left ventricular dysfunction. J Nucl Med 1994;35:707-15.
37. Sawada S, Muzik O, Allman K, et al. Positron emission tomography detects evidence of viability in rest technetium-99m sestamibi defects. J Am Coll Cardiol 1994;23:92-8.
38. Cornel JH, Bax JJ, Visser FC, Fioretti PM. Direct comparison of FDG SPECT with stress-reinjection thallium SPECT and dobutamine echocardiography for predicting rregional improvement after revascularization. J Am Coll Cardiol 1996;27(Suppl A):48A.
39. Skopicki HA, Weissman NJ, Rose GA, et al. Thallium imaging, dobutamine echocardiography and positron emission tomography for the assessment of myocardial viability. J Am Coll Cardiol 1996;27(Suppl A):162A.
40. Arrighi JA, Ng CK, Dey H, Wackers FJT, Soufer R. Resting tc-99m sestamibi SPECT underestimates myocardial viability in patients with severe ishcemic left ventricular dysfunction: comparison with ammonia/FDG PET. J Am Coll Cardiol 1996;27(Suppl A):162A.
41. Lucignani G, Paolini G, Landoni C, et al. Presurgical identification of hibernating myocardium by combined use of technetium-99m hexakis 2-methoxyisobutylisonitrile single photon emission tomography and fluorine-18 Fluoro-2-deoxy-D-glucose positron emission tomography in patients with coronary artery disease. Eur J Nucl Med 1992;19:874-81.
42. Eitzman D, Al-Aouar Z, Kanter HL, et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 1992;20:559-65.
43. Di Carli MF, Davidson M, Little R, et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 1994;73:527-33.
44. Di Carli MF, Asgazadie F, Schelbert HR, et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation 1995;92:3436-44.
45. Beanlands RSB, deKemp RA, Smith S, Johansen H, Ruddy TD. F-18-flourodeoxyglucose PET imaging alters clinical decision making in patients with impaired ventricular function. Can J Cardiol 1996;12(Suppl E):100E. (Abst)
46. Duong TH, Fonarow G, Laks H, et al. Cost effectiveness of positron emission tomography (PET) in the management of ischemic cardiomyopathy patients who are referred for cardiac transplantation. J Am Coll Cardiol 1996,27:144A.
47. Gould KL, Yoshida K, Hess MJ, Haynie M, Mullani N, Smalling RW. Myocardial metabolism of fluorodeoxyglucose compared to cell membrane integrity for the potassium analogue rubidium-82 for assessing infarct size in man by PET. J Nucl Med 1991;32:1-9.
48. Beanlands R, deKemp RA, Scheffel A, et al. Can N-13 ammonia kinetic modeling define myocardial viability independent of F-18 fluorodeoxyglucose. J Am Coll Cardiol. (In press)
49. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: generalizations. J Cereb Blood Flow Metab 1985;5:584-90.
50. Gambhir SS, Schwaiger M, Huang S, et al. Simple noninvasive quantification method for measuring myocardial glucose utilisation in humans employing positron emission tomography and fluorine-18 deoxyglucose. J Nucl Med 1989;30:359-66.
51. Gunther VI, deKemp RA, Ruddy TD, Aung MT, Aubrey BA, Beanlands RS. Quantification of FDG uptake rate using PET detects ischemia in myocardium with normal resting perfusion but significant coronary stenosis. Can J Cardiol 1996;12(Suppl E):117E. (Abst)
52. Abramson B, Ruddy TD, deKemp R, et al. Stress FDG PET imaging as a new approach to the diagnosis of CAD in women.Can J Cardiol 1996;12(Suppl E):156E. (Abst)
53. Mitrani RD, Klein LS, Miles WM, Hackett FK, Burt RW, Wellman HN. Regional cardiac sympathetic denervation in patients with ventricualr tachycardia in the abscense of coronary disease. J Am Coll Cardiol 1993;22:1344-53.
54. Schwaiger M, Kalff V, Rosenspire K, et al. The noninvasive evaluation of the sympathetic nervous system in the human heart by PET. Circulation 1990,82:457-64.
55. Coates G, Chirakal R, Fallen EL, et al. Regional distribution and kinetics of F-18 6-flurodopamine as a measure of cardiac sympathetic activity in humans. Heart 1996;75:29-34.
56. van Warde A, Elsinga PH, Anthonio RL, et al. Study of cardiac recpetor ligands by positron emission tomography. In: van derWall EE, et al, eds. Cardiac Positron Emission Tomography. Amsterdam: Kluwer Academic Publishers, 1995:171-82.
57. Burt RW, Perkins OW, Oppenheim BE, et al. Direct comparison of fluoreine-18-FDG SPECT, fluorine-18-FDG PET and rest thallium-201 SPECT for detection of myocardial viability J Nucl Med 1995;2:179.
58. Muehllehner G, Geagan M, Countryman P, Nelleman P. SPECT scanner with PET coincidence capability J Nucl Med 1995;6:70P. (Abst)